Allison Luo - 14 Nov 2021 Form 4 Insider Report for Prometheus Biosciences, Inc.

Reporting relationship: Chief Medical Officer
Issuer ticker: N/A
Reported as of: 14 Nov 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Nov 2021, 20:06:11 UTC
Prior SEC filing: 15 Sep 2021
Source filing: View source filing
Reporting owner signature: /s/ Timothy K. Andrews, attorney-in-fact for Allison Luo

Key filing fact

Allison Luo filed Form 4 for Prometheus Biosciences, Inc. on 16 Nov 2021.

Key facts

This page summarizes Allison Luo's Form 4 filing for Prometheus Biosciences, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Nov 2021, 20:06.

Change

Previous filing in this sequence was filed on 15 Sep 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RXDX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +113,677
Change %
Price: $0.000000
Shares after: 113,677
Date: 14 Nov 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 113,677
Exercise price: $36.32
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the shares subject to the option will vest on November 14, 2022, and 1/48th of the shares subject to the option will vest monthly thereafter, subject to the Reporting Person's continued service with the Issuer through each vest date.